Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …

PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …

Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …

Background Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become
a major obstacle in improving the clinical outcome of patients with metastatic and advanced …

Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …

Background Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …

Background: Determining the somatic mutations of epidermal growth factor receptor (EGFR)-
pathway networks is the key to effective treatment for non-small cell lung cancer (NSCLC) …

Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced‑stage …

Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …